AtriCure, Inc. (NASDAQ:ATRC) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Atricure Inc. (ATRC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Divisadero Street Capital William Zolezzi | 1,295,706 | $36,331,596 | 4.4% | |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 664,100 | $18,621,364 | +15% | 0.04% |
| 3. | DAFNA Capital Management Nathan Fischel | 641,673 | $17,992,511 | +1% | 4.25% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 451,690 | $12,665,388 | +1% | 0.01% |
| 5. | Millennium Management Israel Englander | 354,145 | $9,930,226 | -63% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.25 | 5,000 | Officer | 103,290 | 2024-05-30 | Filing | |
| $76.68 | 34 | Director | 16,228 | 2021-04-30 | Filing | |
| $40.54 | 12,350 | Director | 41,036 | 2020-11-17 | Filing | |
| $24.86 | 500 | Director | 25,670 | 2019-09-12 | Filing | |
| $17.64 | 11,000 | Director | 16,805 | 2018-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.07 | 3,500 | Director | 8,970 | 2024-08-15 | Filing | |
| $24.09 | 1,500 | Officer | 71,284 | 2024-05-01 | Filing | |
| $30.39 | 1,500 | Officer | 72,784 | 2024-04-01 | Filing | |
| $32.16 | 1,885 | Officer | 50,954 | 2024-03-18 | Filing | |
| $36.72 | 1,500 | Officer | 74,284 | 2024-03-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,766,029 | $170,099,574 | 0% | |
| 2. | 4,193,887 | $149,679,814 | 0% | |
| 3. | 3,394,036 | $121,133,145 | 0.04% | |
| 4. | 2,105,395 | $75,141,548 | 0.44% | |
| 5. | 1,449,726 | $51,741,000 | 0.05% |
News See All
Here’s Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2024 investor letter.
AtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure (ATRC) Stock Slipped on Competition Threat
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to AtriCure’s First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
AtriCure (ATRC) Fell on Competitor Action
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript
AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. AtriCure, Inc.
AtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
AtriCure, Inc. (NASDAQ:ATRC) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to AtriCure's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.